Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
Merck
Colorcon
Harvard Business School

Last Updated: December 9, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NATEGLINIDE

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for NATEGLINIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00097786 Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications Completed Novartis Pharmaceuticals Phase 3 2002-01-01 This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular complications. People in this study cannot have frank diabetes but are considered "borderline" based on blood tests. People in the study take none, one or both of the drugs and do not know which one(s) they are taking.
NCT00189774 Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients Completed Ajinomoto USA, INC. Phase 2/Phase 3 1969-12-31 The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
NCT00189774 Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients Completed Astellas Pharma Inc Phase 2/Phase 3 1969-12-31 The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for NATEGLINIDE

Condition Name

Condition Name for NATEGLINIDE
Intervention Trials
Type 2 Diabetes Mellitus 7
Diabetes Mellitus, Type 2 6
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for NATEGLINIDE
Intervention Trials
Diabetes Mellitus 16
Diabetes Mellitus, Type 2 15
Insulin Resistance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for NATEGLINIDE

Trials by Country

Trials by Country for NATEGLINIDE
Location Trials
Korea, Republic of 5
Japan 5
United States 3
Canada 3
China 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for NATEGLINIDE
Location Trials
Georgia 1
New Jersey 1
Washington 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for NATEGLINIDE

Clinical Trial Phase

Clinical Trial Phase for NATEGLINIDE
Clinical Trial Phase Trials
Phase 4 13
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for NATEGLINIDE
Clinical Trial Phase Trials
Completed 19
Unknown status 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for NATEGLINIDE

Sponsor Name

Sponsor Name for NATEGLINIDE
Sponsor Trials
Novartis Pharmaceuticals 5
Canadian Network for Observational Drug Effect Studies, CNODES 3
Drug Safety and Effectiveness Network, Canada 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for NATEGLINIDE
Sponsor Trials
Other 28
Industry 16
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Mallinckrodt
McKinsey
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.